What exactly did H.C. Wainwright do for PHAR on March 12, 2026?

H.C. Wainwright maintained a Buy rating on Pharming Group N.V. (PHAR) on March 12, 2026, without publishing a new price target, according to a StreetInsider summary.

Does the maintained PHAR analyst rating include a new price target?

No. The research note reiterated a Buy but did not provide a fresh PHAR price target, leaving investors to use company guidance and other analyst reports for valuation.

How should investors interpret the PHAR analyst rating in portfolio decisions?

A maintained Buy shows analyst confidence but is not a guaranteed catalyst. Investors should weigh the PHAR analyst rating against guidance, upcoming catalysts, and Meyka’s B+ grade before changing exposure.

Where can I read the analyst note and related company guidance?

The H.C. Wainwright reiteration is summarized by StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Pharming+Group+%28PHAR%29%3A+%22well+positioned+to+drive+value%22/26151515.html). Company 2026 revenue guidance is covered by Seeking Alpha[

Analyst Ratings

H.C. Wainwright Maintains Buy on Pharming Group N.V. (PHAR) March 2026

ByDanny Kontos March 13, 2026March 13, 2026

H.C. Wainwright maintained a Buy rating on Pharming Group N.V. (PHAR) on March 12, 2026, keeping its positive stance unchanged. The PHAR analyst rating was reiterated in a research note cited by StreetInsider that called the company “well positioned to drive value.” The firm did not disclose a new price target in the published note, and the stock showed a short-term move of -1.55% ($-0.24) after the reiteration. Meyka AI rates PHAR with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.